Grant✓ Small businesses may apply
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
National Institutes of Health
Award ceiling
$400,000
- Opportunity #
- PAR-25-362
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.865
- Status
- posted
- Posted
- Dec 30, 2024
- Closes
- Nov 5, 2028
- Funding instrument
- Grant
- Category
- Health, Income Security and Social Services
- Cost sharing required
- No
Who can apply
- •Public and State controlled institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •For profit organizations other than small businesses
- •Native American tribal governments (Federally recognized)
- •Private institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •County governments
- •Independent school districts
- •City or township governments
- •Special district governments
- •State governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Small businesses
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.
Contact
National Institutes of Health · grantsinfo@nih.gov